Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III KLH-2109 vs leuprorelin in uterine fibroids with menorrhagia
jRCT2031220180Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of linzagolix in Fibromyoma (LM) (2 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Proportion of subjects with low PBAC score from Week 6 to 12. Started Jun 2022; status: completed.
02
Drugs
linzagolix
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on jRCT2031220180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220180.